Cullinan Therapeutics Inc. clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
3 trials changed in the last 30 days: 1 stopped, 1 with a notable change, 1 with a minor change only.
- Notable: CLN-049 · Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Primary and study completion dates pushed to Dec 30, 2029
- Stopped: CLN-978 · Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) Trial terminated
- Minor: CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, · Systemic Lupus Erythematosus Trial sites expanded: 20 → 24 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 1 | 6 | |
| Phase 1/2 | 3 |
Disease areas by active trials
Acute Myeloid Leukemia (AML) (2) · Leukemia (2) · Lung Cancer (2) · Non-Small Cell Lung Cancer (NSCLC) (2) · Lupus (SLE) (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (MDS) (1) · Rheumatoid Arthritis (1)
Get alerts when Cullinan Therapeutics Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.